On the other hand, PRKCI elevated level was generally predicted to enhance the response to PD-L1 blocking-dependent immunotherapies in many cancers (except for ESCA, OV, and TGCT, in which PRKCI level was inversely correlated with PD-L1). The gene discussed is CD274; the disease is cancer.